

FUTURAMEDICAL

PRELIMINARY RESULTS

12 months to 31 December 2020

14 April 2021



DISCLAIMER

This presentation has been prepared by and is the sole responsibility of the directors of Futura Medical plc (the "Company"). This presentation does not constitute a recommendation regarding the shares of the Company nor a representation that any dealing in those shares is appropriate. The Company accepts no duty of care whatsoever to the reader of this presentation in respect of its contents and the Company is not acting in any fiduciary capacity. The information contained in the presentation has not been verified, nor does this presentation purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in the Company. In all cases potential investors should conduct their own investigations and analysis concerning the risks associated with investing in shares in the Company, the business plans, the financial condition, assets and liabilities and business affairs of the Company, and the contents of this presentation.

This presentation (including its contents) is confidential and is for distribution in the United Kingdom only, to persons who are authorised persons or exempted persons within the meaning of the Financial Services and Markets Act 2000 or any Order made thereunder, or to persons of a kind described in Articles 19 or 49 or 50 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) and, if permitted by applicable law, for distribution outside the United Kingdom to professions or institutions whose ordinary business involves them in engaging in investment activities. It is not intended to be distributed or passed on, directly or indirectly, to any other class of persons.

No offer or invitation or solicitation of any offer to acquire securities of the Company is being made now nor does this presentation constitute or form part of any invitation or inducement to engage in investment activity under section 21 of the Financial Services and Markets Act 2000. No reliance may be placed for any purpose whatsoever on the information contained in this presentation or any assumptions made as to its completeness and no warranty or representation is given by or on behalf of the Company nor its directors, employees, agents and advisors as to the accuracy or completeness of the information or opinions contained in this presentation and no liability is accepted by any of them for any such information or opinions, provided that nothing in this paragraph shall exclude liability for any representation or warranty made fraudulently. The information and opinions contained in this presentation are provided as at the date hereof. This presentation is not, and should not be construed as, a recommendation or advice by the Company or its advisers to potential investors to participate in any investment in the Company.

The contents of this presentation are confidential and must not be copied, published, reproduced, distributed or passed in whole or in part to others at any time by recipients. This presentation is being provided to recipients on the basis that they keep confidential any information contained herein or otherwise made available, whether oral or in writing, in connection with the Company.

This presentation may contain certain forward-looking statements. Whilst the directors believe all such statements to have been fairly made on reasonable assumptions, there can be no guarantee that any of them are accurate or that all relevant considerations have been included in the directors' assumptions; accordingly, no reliance whatsoever should be placed upon the accuracy of such statements, all of which are for illustrative purposes only, are based solely upon historic financial and other trends and information, including third party estimates, and may be subject to further verification. Neither the Company nor its directors makes any representation or warranty in respect of the accuracy, completeness or verification of the contents of the Presentation Materials.

In particular, this presentation should not be distributed, published or reproduced in whole or in part or disclosed by recipients to any other person or entity and, in particular, should not be distributed to United States residents, corporations, or other entities, US persons (as defined in Regulation S promulgated under the United States Securities Act of 1933 (as amended), persons with addresses in the United States of America (or any of its territories or possessions), Canada, Japan, the Republic of Ireland, the Republic of South Africa or Australia, or to any corporation, partnership or other entity created or organised under the laws thereof, or in any other country outside the United Kingdom where such distribution may lead to a breach of any law or regulatory requirement. Notwithstanding the foregoing, the Company can distribute this document to US Persons (as defined above), persons with addresses in the United States of America (or its territories or possessions), United States residents, corporations or other entities if the Company is satisfied that an applicable exemption applies. Distribution of this document in the United States of America in the absence of such an applicable exemption may constitute a violation of United States securities law.

FUTURAMEDICAL

A CORPORATE OVERVIEW

ABOUT FUTURA – A CORPORATE OVERVIEW

FUTURAMEDICAL

FUNDAMENTALS

Futura is listed on AIM and located at the Research Park, Guildford

- 'Virtual' organisation with 15 staff and low overheads
- Significant outsourced infrastructure with over 30 consultants

DERMASYS®

Clinically proven transdermal science

- DermaSys® is our proprietary patented transdermal technology platform
- A versatile, clear, odourless gel which is uniquely formulated for each specific therapeutic indication

TRACK RECORD

Clinically proven innovation using existing pharmaceutical compounds

- Sexual health and pain relief focus
- Late stage products with experienced Management Team



PORTFOLIO PRODUCTS

MED3000 – Topical gel for the treatment of erectile dysfunction (ED)

- Highly differentiated treatment with a fast onset of action available without a doctor's prescription (OTC)
- Begins to work immediately in some patients with 60% of patients seeing onset within 10 minutes

CBD100 – Topical gel containing cannabidiol

TPR100 – Topical gel containing diclofenac for the treatment of pain relief



STRATEGIC OUTLOOK

1. Exploiting the potential of our transdermal technology **DermaSys®** and enhancing the Company's position as an innovative research and development company
2. Prioritising resource on our potential US$1 billion sales asset: **MED3000,** a fast acting topical gel to treat erectile dysfunction
3. Maximise MED3000 potential value by conducting FM71 in order to **gain approval in the USA** as a fast acting clinically proven treatment for ED available OTC[1]
4. Following EU approval concluding out-licensing deals to **build sustainable long term revenue stream** and launch **market validation** ahead of US approval
5. Streamlining manufacturing to optimise cost of goods and **build global brand** around the fast acting breakthrough technology that DermaSys® gives MED3000



1. OTC – without the need of a doctor's prescription.

YEAR END HIGHLIGHTS – PRODUCTS, ORGANISATION & FINANCIAL

- Strategic decision to focus on maximising R&D pipeline value by de-risking assets through to approval
- Priorities of completing supplementary MED3000 study (FM71) to enable US approval
- In parallel to focus on several country launches for product validation & subsequent worldwide rollout

MED3000

- Recommendation to award CE mark certificate expected by end of May 2021 giving EU approval for MED3000
- FDA clarity and agreement around remaining supplementary FM71 study required for US approval
- JV signed with Atlantis[1] to fund all regulatory costs to gain approval throughout Asia region[2] & 50/50 profit share
- Specialist corporate advisers appointed to manage commercialisation & out-licensing of MED3000

PAIN RELIEF

- CBD100 in vitro studies supporting stable formulation with enhanced skin permeation of cannabidiol
- Specialist advisers appointed to manage commercialisation options as regulatory landscape becomes clearer
- TPR100 laboratory work confirms enhanced skin permeation of diclofenac but MHRA require full efficacy/safety study to support increased potency

- Net loss in the period: £2.41 million (Net loss 31 December 2019: £8.92 million)
- Cash resource at 31 December 2020: £1.02 million with a further £2 million received post-period end

1.Atlantis Group includes a 100% owned subsidiary Atlantis Investment Management and 60% owned subsidiary Co-High Investment Management. Ms Yang Liu, now Atlantis' Chairperson and Chief Investment Officer, acquired the Atlantis group in 2009.
2. Excludes Japan and South Korea

MED3000 – TOPICAL TREATMENT FOR ED

1

UNIQUE

- ✓ The only rub-on gel clinically proven to treat erectile dysfunction (ED)
- ✓ The only clinically proven ED treatment available for OTC[1] sales throughout Europe

2

BREAKTHROUGH

- ✓ Superior technology helping men get an erection within 10 minutes: faster than tablets
- ✓ Applied by male or partner during foreplay for more natural and spontaneous experience

3

SAFE

- ✓ Drug free medical device, therefore no systemic side effects: unlike tablets
- ✓ No potential for drug with drug interactions with minimal contraindications: unlike tablets

4

BROAD APPEAL

- ✓ Effective in mild, moderate and severe conditions of ED including psychological or organic ED
- ✓ Attributes appeal to many non-users of ED treatments across all ages

1. OTC – without the need of a doctor's prescription.

FUTURAMEDICAL

MED3000

Research & Development

MED3000 MODE OF ACTION





EXTERIOR OVER-THE-COUNTER LABELING – ILLUSTRATIVE ONLY

Eroxon® Gel is a clinically proven treatment for erectile dysfunction in adult men aged 18 years and over

Helps you get and keep an erection hard enough for sex

Directions for use: Massage the contents of one tube onto the head of the penis for 15 seconds, just
before sex.

Do Not Use Eroxon® if:
- You have an allergy to any of the ingredients
- The skin on your penis is red or sore, or appears damaged or broken
- You have been advised by your doctor to avoid sexual activity
- You have a deformed penis

Eroxon® is not a contraceptive and does not contain a spermicide. It will not prevent Sexually
Transmitted Infections (STIs).

Compatible with latex condoms only

MED3000 EU Regulatory Milestones – Class 2B medical device

EU Notified[1] Body Selection	Selection and commission of EU Notified Body	Feb 2020	✓
QMS[2] Update	Updating of Futura's QMS for MED3000	Mar 2020	✓
Application Submission	Submission of MED3000 Technical Dossier	Jul 2020	✓
QMS Approval	Positive opinion issued on QMS for MED3000	Aug 2020	✓
Technical Dossier review – 1st round	First set of questions received and answered	Dec 2020	✓
Technical Dossier review – 2nd round	Second set of questions received and answered	Jan 2020	✓
Internal Clinical Review	Lead reviewer sign-off 2nd clinical review answered	Mar 2021	✓
Final Panel review and CE mark	Final administrative stage OTC designation & certification	May 2021	

Expedited Medical Device Registrations possible in most Middle East, Far East, Africa and Latin America countries based on EU CE Mark

CE mark valid throughout EU but only until 30 June 2023 in Great Britain[3] when post-Brexit requires bridging UKCA mark

1. *Notified Bodies are the regulatory authorities that oversee the approval of medical devices within the EU including the UK*
2. *Quality Management System*
3. *Northern Ireland is exempt from these Brexit provisions & will continue to recognise EU CE mark versus Great Britain's new CE mark to be known as UKCA*

MED3000 US Regulatory Milestones – De Novo medical device

1st Pre-Submission meeting	De Novo classification Discuss existing FM57 clinical data	Feb 2020	✓
2nd Pre-Submission meeting	FDA – New clinical required Discuss route to OTC	Jul 2020	✓
3rd Pre-Submission meeting	Agree supplementary study design & human factor study for OTC	Oct 2020	✓
4th Pre-Submission meeting	Agree supplementary clinical study design – FM71	Mar 2021	✓
5th Pre-Submission meeting	Finalise Human Factors Study Protocol to test OTC label	Q2 2021	
Data Generation	Completion of FM71 & Human Factors study	Q2 2022	
Application Submission	Submission of MED3000's dossier	Q3 2022	
USA Regulatory Approval	USA OTC marketing authorisation	Q1 2023	

"Early interaction with FDA on planned non-clinical and clinical studies and careful considerations of FDA's feedback may improve the quality of subsequent submissions, shorten total review times and facilitate the development process for new devices"

FM71 DESIGN

FM71	A multi-centre, randomised, open label, home use, parallel group, clinical investigation of topically applied MED3000 gel and oral Tadalafil (5mg) tablets for treatment of erectile dysfunction (ED) over a 24 week period
HEADLINE OBJECTIVES	<u>Primary Effectiveness objective:</u> The primary objectives are to show a statistically significant improvement of MED3000 over baseline, and show that the difference from baseline is clinically important <u>Secondary Efficacy objective include:</u> To demonstrate speed of onset of action when the erection is hard enough for penetration (time will be assessed at 5,10 and 15 minutes) <u>Exploratory Effectiveness objectives:</u> • To estimate the difference between MED3000 and tadalafil in improvement compared to baseline using IIEF-EF at 24 weeks • To evaluate the mean change from baseline of the IIEF-EF domain assessed at 4,8,12,16 and 20 weeks post randomisation • To evaluate the proportion of patients achieving a meaningful change on the IIEF-EF (Rosen Criteria) assessed very 4 weeks post randomisation • To evaluate the mean change from baseline in Question 3 and 4 of the IIEF, assessed every 4 weeks post randomisation • To evaluate the mean change from baseline of the other domains of the IIEF, assessed every 4 weeks post-randomisation. • To evaluate the sexual intercourse experience using the Self-Esteem and Relationship (SEAR) questionnaire <u>Safety objectives</u> • Safety of formulations using Adverse Events
STUDY SITES	1 centre in USA & 24 Centres in Central and Eastern Europe (Bulgaria, Poland, Georgia and Slovakia)
PRODUCTS TESTED	MED3000 (single unit dose tubes to deliver 300mg of gel) Tadalafil (5mg) tablet

4 week Run-in period

24 weeks Treatment period

1 week Follow up period



FM71 – FDA AGREEMENT REACHED FEB, 2021 AFTER FOUR Q-SUB MEETINGS

Phase 3, multi-centre, comparative, randomized, open-label, home-use, parallel group study of MED3000 and tadalafil 5mg in 100 subjects

24 week duration	**FDA concern that efficacy may tail off after 12 weeks – not our experience with FM57 study**
Efficacy slightly increased between the 4th and 12th week endpoint	
Least burdensome approach	**100 patients; no placebo (sham) required otherwise clinical study size becomes too large**
Tadalafil 5mg Control	**For comparative purposes only (safety; speed; efficacy)** **Non-inferiority design not required**

FM71 – FDA Agreement reached Feb, 2021 after four Q-sub meetings (cont)

Phase 3, multi-centre, comparative, randomized, open-label, home-use, parallel group study of MED3000 and tadalafil 5mg in 100 subjects

Primary endpoint; clinical significance to be achieved	**MED3000 exceeded minimal clinically important difference of 4 units on IIEF-EF scale (Rosen) in FM57 study; 5.1**
Label Claim	**Statistical design agreed to support onset of action claim of 5, 10 or 15 minutes - 10 minutes achieved in FM57 study**
ED severity	**Include a mix of mild, moderate and severe ED sufferers - as per FM57 study**
Population comparable to US	**Include 20 African Americans in the study (Johns Hopkins centre) - Eastern Europe 80 (some of the centres used in FM57)**

FUTURAMEDICAL

MED3000

Commercial Opportunity

OTC AVAILABILITY OPENS UP LARGE UNTAPPED MARKET

TRADITIONAL SEGMENTS

PDE5i USERS (SATISFIED AND DISSATISFIED)

Drivers of switch to MED3000
- Fast acting, no planning necessary (spontaneity)
- Very favourable side effects profile
- OTC availability

For dissatisfied users the top two are even more relevant.

DIAGNOSED, NOT TREATING

- ~ 20% of ED patients are contra-indicated[1]
- ~ 50% drop out after the first year on oral PDE5i's therapy[2]
- Only 1 in 4 men diagnosed with ED in the USA is on treatment[3]

UNDIAGNOSED, SUSPECTED

- Embarrassment of speaking to the doctor
- Cost and inconvenience
- Huge appeal for OTC availability to overcome barriers

NEWER SEGMENTS

YOUNG MEN

- The prevalence of ED in young men is increasing; now as high as 30%[4]
- Barriers to treatment are even higher for this category and OTC availability fits with their lifestyle.

PARTNERS

- ED treatment is most effective when partner is involved.
- Partners currently feel helpless and frustrated as they want to be more involved.
- They want a more intimate and spontaneous solution

Global ED prescription market $5.6bn (2018)[5]

Significant OTC opportunity

73%[6] of OTC sales would be from patients not currently on treatment

POTENTIAL FOR A NEW OTC CATEGORY

MED3000'S KEY ATTRIBUTES MAKE IT AN ATTRACTIVE OTC TREATMENT

IPSOS FORECAST OF GLOBAL OTC OPPORTUNITY FOR MED3000

$660M[7]

1.Cello Healthcare Consulting research amongst physicians in the US, France and Germany, commissioned by Futura ; 2. Corona G., "First-generation phosphodiesterase type 5 inhibitors dropout (…)", Andrology, 2016, 4, 1002–1009; 3. Frederick L., "Under treatment of erectile dysfunction: claims analysis of 6.2 million patients", J Sex Med, 2014, Oct, (10):2546-53; 4. Nguyen Sex Med Rev. 2017 Oct, vol 5, 508-520; 5. MSP 2018: Data for 75 countries, IQVIA IMS Health; 6. Ipsos research commissioned by Futura 7. Directors' belief based on market research conducted on Company's behalf by Ipsos

SIGNIFICANT COMMERCIAL POTENTIAL

1. **Global ED prescription market worth over US$5.6 billion in 2018[1]**
2. **Potential 1st worldwide OTC product clinically proven to treat ED**
3. **US$660 million potential 'Over the Counter' sales[2]**
4. **Specialist corporate advisors appointed Q3 2020**
5. **Out-licensing discussions with different potential partners for worldwide rights**

IPSOS RESEARCH

	Ipsos scenario		
	Year 3	Year 5	Year 10
RSP ($m)	**500**	**584**	**661**

FUTURAMEDICAL

1 *Manufacturers' Selling Prices 2018: 15 Key ED markets, IQVIA (IMS) Health*
2 *Directors' belief based on Ipsos market research conducted on Company's behalf*

CHINA & SE ASIA – JV ARRANGEMENT

- Joint collaboration with Atlantis Group[1]
- EU approval may facilitate approval in most Asian countries aside China
- Chinese Pivotal study required but all additional R&D costs met by partner
- 50/50 share of profits for region[2]

- ✓ Local expertise and knowledge
- ✓ All further development costs met by partner
- ✓ 50/50 share of profits
- ✓ Significant market potential



1.Atlantis Group includes a 100% owned subsidiary Atlantis Investment Management and 60% owned subsidiary Co-High Investment Management. Ms Yang Liu, now Atlantis' Chairperson and Chief Investment Officer, acquired the Atlantis group in 2009.
2. Excludes Japan and South Korea

MED3000 – ONGOING COMMERCIAL DISCUSSIONS

1. **Specialist corporate advisers retained and running process for other countries (i.e. non-China region)**

2. **Imminent EU certificate strengthens Futura's creditability and clarity around product claims**

3. **Objective of building long term sustainable value**
   Initial target country launches validate commercial opportunity ahead

4. **USA represents the biggest commercial value and sales traction in initial markets will strengthen value proposition**



MED3000 PATENT STRATEGY

Patent protection

- Patents are formulation specific
- First generation patents covers all previous MED formulations
- New patent filed in December 2019 specific to MED3000 with PCT application made in Q4 2020
- Potential to provide patent protection until 2040

Data exclusivity / trademarks

- Special controls under discussion with FDA
- Exclusivity on one key excipient for sexual healthcare
- Certain controls around mode of action specifics of MED3000 which will also be embedded into current IP filing
- Eroxon® trademarked in the EU (OHIM)

MED3000 – A BREAKTHROUGH CLINICALLY PROVEN TREATMENT FOR ED

- First OTC gel to treat ED, clinically proven with a rapid speed of onset imminent approval throughout EU[1]
- Clear regulatory pathway with small confirmatory study for likely OTC approval in USA
- 50/50 joint collaboration signed for Asia region with all remaining R&D cost borne by partner
- Advanced discussions for other commercial deals in other regions / countries

1. *EU includes UK*
2. *Illustrative pack design only*

FUTURAMEDICAL

Pain Relief

TOPICAL CANNABIDIOL WITH DERMASYS®- CBD100

- Joint venture signed with CBDerma Technology to fund development of DermaSys® based cannabidiol formulation
- Providing a near term opportunity under cosmetic regulations as a superior product in respect of absorption
- Longer term CBD100 could be supported with strong clinical evidence for registration as a drug (medicinal) product
- Patent application filed in August 2020 – Search report confirming innovation
- Specialist advisers retained to explore commercialization options

SUPERIOR IN-VITRO PERMEATION

INTO THE SKIN



THROUGH THE SKIN



TOPICAL PAIN RELIEF – TPR100

1	Global sales of over the counter topical analgesics US$ 4.9 billion[1]
2	Demand for safe, effective and long lasting topical pain relief DermaSys® provides **faster drug permeation**, a key point of difference
3	**TPR100** is a Diclofenac gel that utilises Futura's DermaSys® technology **Improved permeation** compared to market leaders at same dosage

GSK's Voltaren Arthritis Pain Gel now over the counter in USA market creating potential opportunity for TPR100



1	• **Agreement signed with Thornton & Ross (part of STADA) for UK rights** • **Lab work confirmed strong permeation claims of TPR100** • **MHRA requiring efficacy and safety study to support TPR100 potency**
2	• **Recent FDA diclofenac switch creates US opportunity** • **Exploring efficacy study to satisfy FDA and MHRA requirements** • **Subject to resource requirements**

1 – Mid year to 2017, Nicholas Hall 's OTC Reports, Analgesics The Evolving Self-Care market for pain relief

FUTURAMEDICAL

FINANCIAL RESULTS & OUTLOOK

YEAR END HIGHLIGHTS – FINANCIALS

- Net loss of £2.41 million in period of which £1.93 million was related to R&D (2019: Net loss £8.92 million)
- Cash resources of £1.02 million; with a further £2 million received post-period end:
  - £2.0 million investment completed March and April 2021
  - £0.5 million tax credit refund due mid 2021
- Current cash resources sufficient to Q1 2022
- Exploring funding options for FM71 through advanced commercial discussions and other potential dilutive and/or non-dilutive sources

OUTLOOK

1. MED3000 CE Mark expected by end of May to enable potential launch in EU and facilitate ‘fast track’ regulatory approval through many countries world-wide other than US & China
2. Agreement reached with FDA over supplementary study to enable US approval
   JV reached with Atlantis for Asia including supplementary study to enable China approval
3. Specialist corporate advisers retained; 50/50 JV signed for Asia region and further commercial deals expected during 2021 ahead of initial market launches
4. Updates on commercial development of CBD100 – topical cannabidiol formulation using DermaSys®